---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000081"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:03:03.397662+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q2 record revenues $211.4M, EPS $0.36; lifts FY guidance

## Summary
- Q2 net revenue $211.4M (+53.1% YoY); GAAP EPS $0.36 vs ($0.14); record adjusted EBITDA $54.1M (+62.8%).
- Rare Disease rev $104.0M (Cortrophin Gel $81.6M, +66%; ILUVIEN/YUTIQ $22.3M).
- Generics rev $90.3M (+22.1%); driven by new launches including first-to-market prucalopride.
- Raised FY2025 guidance: rev $818M–$843M; adj EBITDA $213M–$223M; adj EPS $6.98–$7.35.
- Cash & equivalents $217.8M; year-to-date CFO $110.8M.

## SEC filing metadata
- accession: 0001023024-25-000081
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/0001023024-25-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/ani-20250808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000081
- JSON: https://secwatch.observer/filing/0001023024-25-000081.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.